论文部分内容阅读
目的探讨氨溴索联合孟鲁司特钠在治疗难治性哮喘的过程中的疗效和对患者肺功能的影响。方法 98例难治性哮喘患者随机分为观察组与对照组,各49例。对照组采用氨溴索治疗;观察组实施氨溴索+孟鲁司特钠治疗。观察两组患者治疗前后的肺功能变化及疗效。结果两组治疗后肺功能指标均明显改善(P<0.05),且观察组优于对照组(P<0.05);观察组治疗总有效率为87.76%,明显高于对照组的61.22%(P<0.05)。结论氨溴索联合孟鲁司特钠治疗难治性哮喘的疗效较好,对患者肺功能的影响较小,可临床应用。
Objective To investigate the efficacy of ambroxol combined with montelukast sodium in the treatment of refractory asthma and its impact on lung function. Methods A total of 98 patients with refractory asthma were randomly divided into observation group and control group, 49 cases each. The control group was treated with ambroxol; the observation group was treated with ambroxol + montelukast sodium. The changes of pulmonary function and the curative effect of the two groups before and after treatment were observed. Results The lung function indexes of the two groups were significantly improved (P <0.05), and the observation group was better than the control group (P <0.05). The total effective rate of the observation group was 87.76%, significantly higher than that of the control group (P <0.05). Conclusion Ambroxol combined with montelukast sodium is effective in the treatment of refractory asthma, and has little effect on pulmonary function in patients. It can be used clinically.